Viridian Therapeutics received FDA approval for veligrotug for thyroid eye disease, initiating direct competitive pressure on Amgen’s Tepezza. Viridian’s drug will be marketed as Lumvoa, and the company said pricing will be set “in line with” Tepezza, positioning it for uptake in a market dominated by the existing standard. The approval adds another mechanism-backed option in a disease area where biologic treatment selection increasingly depends on tolerability and response durability. For the competitive landscape, the timing matters: Tepezza’s dominance now faces a fresh FDA-approved challenger, with implications for formulary access and prescribing behavior.